Phase 2 trial comparing sorafenib, pravastatin, their combination or supportive care in HCC with Child–Pugh B cirrhosis
-
Published:2021-01-09
Issue:1
Volume:15
Page:93-104
-
ISSN:1936-0533
-
Container-title:Hepatology International
-
language:en
-
Short-container-title:Hepatol Int
Author:
Blanc Jean-Frédéric, Khemissa Faiza, Bronowicki Jean-Pierre, Monterymard Carole, Perarnau Jean-Marc, Bourgeois Vincent, Obled Stéphane, Abdelghani Meher Ben, Mabile-Archambeaud Isabelle, Faroux Roger, Seitz Jean-François, Locher Christophe, Senellart Hélène, Villing Anne-Laure, Audemar Franck, Costentin Charlotte, Deplanque Gaël, Manfredi Sylvain, Edeline JulienORCID, Boucher Evelyne, Talarmin Marie, Le Sourd Samuel, Vergniol Julien, Gagnaire Alice, Bedenne Laurent, Jouve Jean-Louis, Hillon Patrick, Lepage Côme, Minello Anne, Barraud Hélène, Lecomte Thierry, Barbieux Jean-Pierre, Wolff Patrice, Phoutthasang Valérie, Belletier Christine, Archambeaud Isabelle, Budnik Tamara Matysiak, Schnee Matthieu, Duluc Muriel, Monnereau Emmanuelle Norguet, Bennouna Jaafar, Hiret Sandrine, Gatineau Michel, Ramdani Mohamed, Le Bricquir Yann, Ganne-Carrie Nathalie, Bourcier Valérie, Pilette Christophe, Dauvois Barbara, Baconnier Mathieu, Michel Pierre, Thevenet Philippe, Cosme-Gassmann Hélène, Habersetzer François, Coltescu Camélia, Pauwels Mathieu, Brissonneau Sophie Nahon, Egreteau Joëlle, Desrame Jérôme, Auby Dominique, Texereau Patrick, Etienne Pierre-Luc, Dourthe Louis-Marie, Tazi Youssef,
Funder
institut national du cancer Sanofi Pasteur
Publisher
Springer Science and Business Media LLC
Reference29 articles.
1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018;68:394–424 2. Bertuccio P, Turati F, Carioli G, et al. Global trends and predictions in hepatocellular carcinoma mortality. J Hepatol 2017;67:302–309 3. Galle PR, Forner A, Llovet JM, et al. EASL Clinical Practice Guidelines: management of hepatocellular carcinoma. J Hepatol 2018;69:182–236 4. Heimbach JK, Kulik LM, Finn RS, et al. AASLD guidelines for the treatment of hepatocellular carcinoma. Hepatol Baltim Md 2018;67:358–380 5. Marrero JA, Kulik LM, Sirlin CB, et al. Diagnosis, staging, and management of hepatocellular carcinoma: 2018 practice guidance by the American Association for the Study of Liver Diseases. Hepatol Baltim Md 2018;68:723–750
Cited by
27 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Statin therapy: a potential adjuvant to immunotherapies in hepatocellular carcinoma;Frontiers in Pharmacology;2024-02-01 2. Metabolic reprogramming in the tumor microenvironment of liver cancer;Journal of Hematology & Oncology;2024-01-31 3. The lipid droplet in cancer: From being a tumor‐supporting hallmark to clinical therapy;Acta Physiologica;2024-01-22 4. The Impact of Statins on the Survival of Patients with Advanced Hepatocellular Carcinoma Treated with Sorafenib or Lenvatinib;Cancers;2024-01-05 5. Multidisciplinary treatment of hepatocellular carcinoma in 2023: Italian practice Treatment Guidelines of the Italian Association for the Study of the Liver (AISF), Italian Association of Medical Oncology (AIOM), Italian Association of Hepato-Bilio-Pancreatic Surgery (AICEP), Italian Association of Hospital Gastroenterologists (AIGO), Italian Association of Radiology and Clinical Oncology (AIRO), Italian Society of Pathological Anatomy and Diagnostic Cytology (SIAPeC-IAP), Italian Society of Surgery (SIC), Italian Society of Gastroenterology (SIGE), Italian Society of Medical and Interventional Radiology (SIRM), Italian Organ Transplant Society (SITO), and Association of Patients with Hepatitis and Liver Disease (EpaC) – Part II – Non-surgical treatments;Digestive and Liver Disease;2023-12
|
|